Magnetic resonance study on the binding ability between targeted neuropilin-1 probe and ectopic glioma in mice
10.3760/cma.j.issn.1674-6554.2018.05.003
- VernacularTitle:靶向神经纤毛蛋白-1的分子探针与小鼠异位胶质瘤结合的磁共振研究
- Author:
Xinxin WANG
1
;
Yuheng SHAN
;
Chunrong LIU
;
Shijiang ZHONG
Author Information
1. 天津中医药大学
- Keywords:
Neuropilin-1;
Ectopic glioma model;
Magnetic resonance imaging;
Prussian blue stain;
Mice
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2018;27(5):395-399
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the binding ability of the molecular probe of neuropilin-1( NRP-1) to mouse ectopic glioma by magnetic resonance imaging ( MRI) . Methods Glioma model mice were pre-pared by glioma tissue transplantation.Thirty tumor bearing mice were randomly selected for tissue anatomy(n=12) and other 18 mice were randomly divided into 3 groups:the control group ( group A) ,the probe con-trol group (group B) and the probe group (group C),which were given 20 μl saline,20 μl USPIO-PEG, 20μl USPIO-PEG-tLyP-1 through the tail vein of the mice respectively.And at 0h,6h,12h,24h after admin-istration,T2WI and T2MAPPING sequences were detected by MRI. Then the tumor bearing mice were killed immediately and the glioma tissue was used to detect the iron content by Prussian blue staining to detect the binding ability of the glioma tissue with the new molecular probe. The biological toxicity of the new molecular probe was detected by pathological staining. Results The expression of NRP-1 in glioma tissues was signifi-cantly higher than that in the liver,kidney and brain(P<0.05).The 24h relaxation time ((14.19±0.87)ms) of the glioma tissue in the C group was significantly lower than that in the B group ((25.94±0.77)ms) (P<0.05) ,and the blue staining particles in the C group were more than those in the B group(P<0.05) . Conclu-sion In the animal experiment,the molecular probe with NRP-1 as the target has obvious targeting effect and good biocompatibility,which provides a clinical basis of glioma for further clinical diagnosis.
